Based on the provided sources, there is no specific information regarding discount terms for Yervoy (ipilimumab). However, we can provide some general information about the drug and potential ways to access it at a lower cost.
Yervoy is a brand name for the drug ipilimumab, which is used for the treatment of certain types of cancer, including melanoma and advanced renal cell carcinoma [2]. It is an immunotherapy drug that works by activating the body's immune system to fight cancer cells [2].
When it comes to accessing Yervoy at a lower cost, there are a few options to consider:
1. Patient Assistance Programs: Bristol-Myers Squibb, the manufacturer of Yervoy, offers a patient assistance program called BMS Access Support. This program provides financial assistance to eligible patients who cannot afford their medication. It is recommended to contact the program directly to inquire about the specific discount terms and eligibility criteria [2].
2. Insurance Coverage: Check with your health insurance provider to see if Yervoy is covered under your plan. Some insurance plans may cover a portion or all of the cost of the drug, depending on the specific policy and the patient's medical condition.
3. Generic Alternatives: Although Yervoy is a brand-name drug, there may be generic alternatives available. Generic drugs are usually less expensive than their brand-name counterparts. It is important to consult with a healthcare professional to determine if a generic alternative is suitable for your specific medical condition.
4. Clinical Trials: Participating in a clinical trial can be an option for accessing Yervoy at a reduced cost or even for free. Clinical trials are research studies that test the safety and effectiveness of new drugs or treatment approaches. However, participation in a clinical trial may require meeting specific eligibility criteria and considering potential risks and benefits.
It is essential to consult with a healthcare professional, such as an oncologist or pharmacist, to discuss the available options for accessing Yervoy at a lower cost. They can provide personalized advice based on your specific situation and guide you through the process.
Sources:
[1] DrugPatentWatch: Yervoy (ipilimumab) - https://www.drugpatentwatch.com/p/biologics/tradename/YERVOY
[2] National Cancer Institute: Ipilimumab - https://www.cancer.gov/publications/dictionaries/cancer-drug/def/ipilimumab
[3] Bristol-Myers Squibb: Bristol-Myers Squibb and Nektar Therapeutics Announce Global Development & Commercialization Collaboration for Nektar's CD122-biased Agonist NKTR-214 - https://news.bms.com/news/partnering/2018/Bristol-Myers-Squibb-and-Nektar-Therapeutics-Announce-Global-Development--Commercialization-Collaboration-for-Nektars-CD122-biased-Agonist-NKTR-214/default.aspx